One possible reason for the poor immunogenicity of tumors is the induction of peripheral tolerance by tumor cells that fail to deliver costimulatory signals. Furthermore, T cells stimulated with wild-type tumor cells often fail to secrete cytokines. The present study has been undertaken to identify cytokines that cooperate with CD80 in T-cell activation in vitro toward human breast and ovarian carcinoma cell lines. Tumor cell-mediated T-lymphocyte activation was analyzed directly in allogeneic mixed lymphocyte/tumor cell cultures as proliferation and effector functions were assessed in cytotoxic T-cell assays. Interleukin-7 (IL-7) amplified the proliferative response toward CD80-transfected breast and ovarian carcinomas and stimulated predominantly CD4 ϩ T lymphocytes.
T he signaling events initiated when T-cell receptor binds peptide ligand in the context of the major histocompatibility complex (MHC) define the specificity of an immune response and enable the development of T-cell functional ability. Depending upon the nature of the stimulus, T lymphocytes can be fully activated, partially activated, or become tolerant. The delivery of "signal 1" via the T-cell receptor without an accompanying costimulatory signal (termed "signal 2") results in a state referred to as anergy. [1] [2] [3] Costimulatory signals are provided with the interaction of several T-lymphocyte adhesion molecules with their respective ligands on antigen (Ag)-presenting cells (APCs). [1] [2] [3] [4] They lead to downstream events that control the expression of genes, including those for interleukin-12 (IL-12), and eventually other cytokines. CD80 (B7-1) and CD86 (B7-2), which are expressed on dendritic cells, activated macrophages, and B cells, seem to be the most important molecules in delivering costimulatory signals. 4 -7 The interaction of CD80 and/or CD86 with its receptor, CD28, leads to the activation of resting T cells by an augmentation of lymphokine secretion. 8 -10 Furthermore, antibody (Ab)-mediated signaling via the CD28 receptor was shown to prevent the induction of anergy. 10, 11 In contrast to CD28, CTLA-4, the second ligand for CD80/CD86, has been shown to be a negative regulator of T-cell activation. [12] [13] [14] Because carcinomas commonly express MHC class I molecules, and because several tumor-specific Ags have been defined that could be targeted by cytotoxic T lymphocytes (CTLs) (reviewed in Ref. 15 ), a possible reason for the poor immunogenicity of tumors is the induction of peripheral tolerance by tumor cells that fail to deliver costimulatory signals. We and others have demonstrated that supplying missing costimulatory signals by the transfection of CD80 into tumor cells facilitates the generation of tumor-reactive human CTLs in vitro 16 -19 and leads to the suppression of tumor growth in several animal models. 20 -23 However, these experiments also indicated that CD80 transfection alone may not be sufficient to activate CTLs and suggested that additional molecules may be required. The optimal triggering of tumor-specific CTL responses requires T-cell help that could be provided by the expression of MHC class II molecules either by transfection or, in cases in which MHC class II expression on tumor cells could be up-regulated, by interferon-␥ (IFN-␥) treatment and/or tumor necrosis factor-␣ (TNF-␣) treatment. The coexpression of CD80 and MHC class II resulted in the effective induction of MHC class I-restricted tumor immunity, which was mediated in part by CD4 ϩ T helper (Th) lymphocytes. 18, 19, 24 Alternatively, the requirement for helper cells and APCs could be bypassed by the addition of appropriate cytokines. [25] [26] [27] [28] [29] [30] [31] One consequence of the poor immunogenicity of tumors is that specifically reacting T lymphocytes often fail to secrete cytokines, which are important for their differentiation and propagation. The direct modification of tumor cells using cytokine-DNA including IL-2, IL-4, IL-7, IL-12, TNF-␣, IFN-␥, and GM-CSF as a strategy to support host immunity has been studied intensively in several animal models. [25] [26] [27] [28] [29] [30] [31] A variety of specific and unspecific immune reactions involving T lymphocytes, natural killer (NK) cells, and macrophages could be involved in tumor rejection.
In this study we focused on two cytokines, IL-12 and IL-7, because they were described to be of particular importance in the context of costimulation: IL-12 was originally described as a factor promoting NK cell and CTL activity. 32, 33 More recently, IL-12 has been found to modulate IFN-␥ secretion and to induce the maturation of Th type 1 (Th1) cells. 34, 35 Furthermore, IL-12 was demonstrated to synergize with CD80/CD28 interactions in inducing efficient proliferation and cytokine production of murine and human T lymphocytes. 36 -39 IL-7 was initially described as a growth factor for B-cell precursors in vitro but subsequently has been demonstrated to promote tumor rejection via the expansion of CD8 ϩ T lymphocytes and the activation of CTL effector functions. 40 -43 IL-7 is also described as a potent costimulus involving the CD28 activation pathway and shows synergistic effects with IL-12 on human T-cell activation. [44] [45] [46] The aim of the present study was the identification of cytokines that cooperate with CD80 in T-lymphocyte activation toward human breast and ovarian carcinoma cells. We showed previously that CD80 expression is necessary for tumor cells to function as alloantigenpresenting cells. In the present report, we tried to develop culture conditions that would allow us to modulate the immune responses toward genetically modified tumor cells by IL-7 and IL-12, thus leading to the propagation of tumor-reactive T lymphocytes.
MATERIALS AND METHODS

Cell lines and culture conditions
The breast carcinoma cell line KS was established from a pleural effusion of a female patient. The ovarian carcinoma cell line GG was derived from a malignant ascites effusion of an ovarian cancer patient. Both tumor cell lines were established in our laboratory and were grown adherently in tissue culture flasks in Dulbecco's modified Eagle's medium (Life Technologies, Eggenstein, Germany) supplemented with 10% fetal calf serum (BioWhittaker, Walkersville, Md), 2 mM L-glutamine, and 1% penicillin/streptomycin (Life Technologies). The CD80-transfected variants KS24 and GG8 have been described previously 19 and were maintained as their nontransfected parental counterparts, with the exception of G418, which was supplemented at 0.5 mg/mL. To enhance the expression of MHC class I and class II and several adhesion molecules with costimulatory functions, tumor cells were cultured for 48 hours in complete medium containing TNF-␣ (5 ng/mL) and IFN-␥ (500 U/mL) (both provided by Boehringer Mannheim, Mannheim, Germany) as described previously. 19 The NK-sensitive erythroblastoid cell line K562 and the Epstein-Barr virus-transformed B lymphoid cell line Laz509 were maintained in RPMI 1640.
Peripheral blood mononuclear cells were isolated from the heparinized blood of healthy donors by Ficoll-Hypaque (Biochrom, Berlin, Germany) density centrifugation. T cells were purified after an adherence step on plastic dishes and subsequent rosetting with sheep erythrocytes (ICN, Meckenheim, Germany). Preactivated T-cell blasts were obtained by incubating resting T cells with phytohemagglutinin (PHA)-L (Boehringer Mannheim) at a final concentration of 1 g/mL. Mitogen-activated T lymphocytes were harvested for stimulation experiments and washed intensively after 7 days of PHA stimulation to minimize the background proliferation of T-cell blasts collected at an earlier timepoint.
Human histocompatibility leukocyte Ag (HLA) typing of tumors and T lymphocytes Effector T cells of healthy donors and stimulator cells were HLA-A2-matched. Expression of the HLA-A2 allele was determined by immunofluorescence using the monoclonal Ab (mAb) BB7.2 (American Type Culture Collection (ATCC), Manassas, Va). The A0201* subtype was confirmed in the Department of Immunohematology and Blood Bank (University Hospital, Leiden, The Netherlands) using specific polymerase chain reaction primers. The HLA phenotypes of the tumor cell lines were determined by the Blood Bank, University of Heidelberg: KS (HLA-A2, HLA-B35,60, HLA-C3,4, HLA-DRB1*15,1302, HLA-DQB1*0602,0604, and HLA-DQA1*0102,0102), GG (HLA-A2,32, HLA-B7,27, HLA-C1,7, HLA-DRB1*08,11,HLA-DQB1*04,0301, and HLA-DQA1*0401,0501).
Quantitative flow cytometry
Immunofluorescence analysis was performed on a FACScan cytometer (Becton Dickinson, Heidelberg, Germany) as described previously. 18, 19 All immunofluorescence reagents were pretitrated. The following unconjugated mAbs were used in combination with goat F(abЈ) 2 anti-mouse immunoglobulin (G plus L)-fluorescein isothiocyanate (Tago, Camarillo, Calif) as a second-stage reagent: anti-HLA-A2 (BB7.2, ATCC), anti-CD56 (T199, Dianova, Hamburg, Germany), and anti-CD80 (MAB104, Dianova). The secondary Ab alone was used as negative control. Anti-CD3 (UCHT-1), anti-CD4 (13B8.2), anti-CD8 (B9.11), anti-CD25 (B1.49.9), and anti-CD28 (CD28.2) (all from Dianova) were used as phycoerythrin and fluorescein isothiocyanate conjugates, respectively, in twocolor immunofluorescence. 
Propagation of T lymphocytes
T cells of healthy donors (1 ϫ 10 6 cells/well) were cocultured with irradiated allogeneous KS or KS24 breast carcinoma cells (1 ϫ 10 5 cells/well) in 24-well culture plates (2 mL/well) in complete RPMI 1640 containing 10% human sera (BioWhittaker). T lymphocytes and stimulator cells were HLA-A2-matched. Cultures were restimulated at weekly intervals at a lymphocyte to tumor cell ratio of 10:1. The cultures contained different cytokines as indicated: rIL-7 was added at 1 ng/mL from the beginning of the stimulations; rIL-12 was added on day 7 (start of the second stimulation) at a final concentration of 0.1 ng/mL. On day 3 of the second stimulation (day 10), all cultures were adjusted to 30 U/mL rIL-2.
Cytotoxicity assay
Cell-mediated cytotoxicity was tested in a standardized 51 Cr release assay using 1 ϫ 10 3 target cells/well. The 51 Cr-labeled target cells were incubated with effector cells at different effector to target (E:T) ratios in V-bottom microtiter plates (Nunc). In blocking studies, target cells were preincubated at 4°C for 15 minutes with anti-MHC class I mAb (W6/32, 10 g/mL, ATCC). Cold target inhibition experiments were performed by adding a 50-fold excess of unlabeled K562. Microcultures were set up in triplicate and were spun down following a 3-hour incubation. Subsequently, supernatants were collected and counted in a gamma counter. Specific lysis was calculated according to the following formula % lysis ϭ ([test release Ϫ spontaneous release]/[maximum release Ϫ spontaneous release]) ϫ 100.
Spontaneous and maximum releases were determined by incubating targets without effector cells in medium alone and with 1% sodium dodecyl sulfate, respectively.
To facilitate a comparative analysis of cytolytic activity, results were expressed as lytic activity (LA). One LA was defined as percent lysis at an E:T ratio of 30:1 multiplied by the total number of effector cells generated.
RESULTS
IL-12 represses the proliferative response of resting peripheral blood mononuclear cells toward CD80-transfected breast and ovarian tumor variants in primary stimulations
We demonstrated previously that CD80-expressing breast and ovarian tumor cell transfectants, in contrast to nontransfected tumor cell lines, stimulated the proliferation of allogeneic resting T lymphocytes in vitro; proliferation was enhanced further by pretreating tumor cells with TNF-␣ and/or IFN-␥. 19 The influence of IL-12 on the activation of the T lymphocytes induced by CD80 ϩ KS24 (breast carcinoma) and GG8 (ovarian carcinoma) variants is shown in Figure 1A . Increasing Because a cooperative effect between CD28/CD80-mediated costimulation with preactivated T cells has been observed previously, 36, 39, 47 we performed similar experiments with PHA-activated T-cell blasts. As shown in Figure 1B , increasing concentrations of IL-12 induced a modest proliferation of PHA-preactivated T-cell blasts that was not enhanced by the untransfected parental cell lines KS and GG. In case of the CD80-expressing KS24 tumor variant, IL-12 augmented T-cell proliferation in a dose-dependent fashion up to a 15-fold higher magnitude. IFN-␥/TNF-␣ preincubation of KS24 transfectants further increased their stimulating potential in comparison with untreated KS24 cells. IL-12 also augmented T-lymphocyte proliferation toward the CD80-transfected GG8 tumor variant. However, GG8 tumor cells only induced proliferation following treatment with IFN-␥ and/or TNF-␣, as shown previously. 19 Our experiments indicate that a cooperative effect between IL-12 and CD80-expressing tumor transfectants was only observed with preactivated T lymphocytes, but not with naive T cells.
Kinetic experiments, as shown in Figure 2 , demonstrated that IL-12 strongly suppressed the proliferation of naive T cells toward the KS24 transfectant only when added during the early induction phase of the immune response. Addition of the cytokine at a later time (day 1 or day 3) showed only slight suppressive effects on the proliferation rate (Fig 2A) . Similarly, the augmentation of the response of preactivated T cells by exogenous IL-12 was maximal when added during the first 24 hours of stimulation (day 0) (Fig 2B) .
In contrast to primary stimulations, IL-12 augments T-cell responses and synergizes with CD80-mediated activation in secondary stimulations
To determine whether IL-12 induces a long-lasting unresponsiveness of naive T lymphocytes, we performed rechallenge experiments (Fig 3) . As illustrated previously, IL-12 inhibited the proliferative response of resting T lymphocytes toward stimulator cells during the primary stimulation (Fig 3A) . T cells primed separately with KS and KS24 in either the absence or presence of IL-12 (1000 pg/mL) were then restimulated after 5 days with the same Ag (Fig 3B) . Only KS24-primed T lymphocytes could be reactivated. Independent of the presence of IL-12 in the primary stimulation, increasing IL-12 concentrations in restimulation experiments augmented T-cell proliferation in a dose-dependent manner. The results shown in Figure 3 are representative of three independent experiments with T cells from three different donors. Comparable results were obtained with the ovarian tumor cell line GG and the corresponding CD80-expressing variant (data not shown). These experiments indicate that IL-12 may cooperate with CD80 in the generation of tumor-reactive T-cell lines when used under appropriate conditions. Figure 4 demonstrates that IL-7 amplifies the proliferative response of naive T cells toward the KS24 breast carcinoma variant by Յ1.5-fold (Fig 4A) and toward cytokine-preincubated GG8 ovarian carcinoma transfectants by Յ6-fold (Fig 4B) . However, we also observed that T cells, cultivated either alone or together with nontransfected tumor cells, responded to IL-7 in a dose-dependent fashion. This finding indicates that IL-7 supports T-cell proliferation independent of the presence of Ag or CD80, but can also augment the response toward CD80-expressing tumor variants in an additive manner.
IL-7 promotes proliferation of T lymphocytes preactivated by CD80-transfected tumor cells
IL-12 and IL-7 synergize with CD80-mediated costimulation in inducing efficient proliferation of cytolytic long-term T-cell cultures To assess the proliferative and functional activity as well as the phenotype of T cells that respond to KS variants under different culture conditions, we performed longterm mixed lymphocyte tumor cell cultures (MLTCs) that were stimulated separately with IFN-␥/TNF-␣-pretreated KS and KS24 cells. The growth kinetics of T lymphocytes of one representative healthy donor are shown in Figure 5 . The addition of IL-7 or IL-12 (beginning on days 0 and 7, respectively) to cultures stimulated with parental IFN-␥/TNF-␣-pretreated KS cells did not lead to long-term T-cell lines. Importantly, the expansion of T lymphocytes stimulated with KS24 was clearly supported by IL-12 or IL-7 up to two logarithmic units, demonstrating that both ILs cooperate with CD80 costimulation in long-term T-cell propagation. Similar results were obtained with two different T-cell donors; however, one donor gave rise to stable T-cell lines only following stimulation with KS24 in combination with IL-7 or IL-12, but not without cytokines (see Table 1 ).
All cultures generated under the conditions described above contained predominantly CD3 ϩ T cells (93-99%) and only small amounts of CD56 ϩ cells (0.2-6%) that were preferentially detected in cultures containing IL-12. IL-7 supported the propagation and activation of CD4 ϩ T cells, whereas IL-12 promoted the development of CD8 ϩ T-cell lines. The CD4/CD8 ratios of the T-cell lines generated from all three donors are presented in Table 1 . T cells activated with KS24 cells expressed CD28 during the initial phase of the stimulation, which decreased toward later timepoints (after day 35) (data not shown). Table 1 also summarizes the cytolytic activity of T-lymphocyte cultures generated by stimulation with KS or KS24 cells in the presence of IL-7 and IL-12, respectively. T cells propagated with the parental KS cell line showed either no LA or weak LA toward KS target cells, especially when an excess of K562 cells was added to block NK activity. Stimulation with KS24 cells in the absence of IL-7 or IL-12 gave rise to CTLs in two of three donors. IL-7 increased the potential of KS24 cells to induce CTLs to a variable degree. However, the In all stimulation protocols, the cultures were adjusted to 30 U/mL IL-2 on day 7. IL-7 was added on day 0 of culture, whereas IL-12 was given after T cell priming for 7 days with tumor cells and IL-2 alone. T lymphocytes were restimulated and counted every 7 days. Representative growth kinetics of lymphocytes from one of three healthy donors are shown.
strongest LA toward KS cells and the lowest NK activity (cytolysis of K562, data not shown) were observed when KS24 cells were used to stimulate T cells in the presence of IL-12. This finding was more obvious when cells were analyzed on day 64. To examine whether this reactivity against KS tumor cells was MHC-restricted, blocking experiments using mAbs were performed. As shown in Figure 6 , the cytolysis of KS tumor cells was inhibited by an MHC class I-specific mAb (84% inhibition, data shown for donor 1).
DISCUSSION
The modification of malignant cells with genes coding for costimulatory molecules such as CD80 is aimed at endowing tumor cells with professional Ag-presenting competence. Current studies have demonstrated that CD80 expression on tumors is already necessary, yet insufficient to elicit T-cell responses, and that the addition of appropriate cytokines still improves the generation of tumor-reactive T lymphocytes. Thus, IL-12 and IL-7 were reported to enhance the therapeutic effect of murine CD80-transfected tumor vaccines. 28, 37, 38, 43, 44, 48 By analyzing the proliferative response as a parameter for T-cell activation in allogeneic MLTCs, we observed that IL-12 exerted a bimodal function on the stimulation of T cells by CD80-transfected breast and ovarian cancer cell lines. Although IL-12 inhibited the primary T-cell proliferation, the response of activated T cells was augmented by IL-12 when rechallenged with the same CD80-transfected tumor cells. A synergy between CD80-mediated costimulation and IL-12 on preactivated T cells has been demonstrated previously with murine Th1 clones and human PHA-activated T-cell *Phenotypic analysis of permanent T cell lines was performed on day 70 by immunofluorescence. †The cytolytic response of T cells was tested against KS targets under "cold" target competition with unlabeled K562 cells at an inhibitor to target ratio of 50:1. Lysis of targets was assessed in a 51 Cr release assay at four different E:T ratios. The results presented here were calculated and converted in LA as described in Materials and Methods.
‡Allogeneic T lymphocytes were stimulated weekly with CD80-transfected (KS24) or nontransfected (KS) breast tumor cells as described in Figure 5 .
§Stimulator cells were pretreated with a combination of TNF-␣ (25 ng/mL) and IFN-␥ (500 U/mL) for 48 hours. ¶Insufficient expansion of T cells, analysis not possible. blasts. 36, 39 An inhibition of primary T-cell activation was also observed in a study performed with CD80-transfected melanoma cells. 47 Interestingly, this inhibitory effect was only observed with CD80, but not CD86-transfected melanoma cells, which is in concordance with a functional difference of both molecules. Preliminary results indicate that the inhibition of primary T-cell activation induced by CD80-transfected breast and ovarian cancer cells is mediated through IFN-␥. Confirming earlier observations, IFN-␥ does not always function in the same direction (i.e., seems to be an early activation signal for T lymphocytes and a late signal to switch off this response through the induction of apoptosis). 49, 50 These contrasting effects seemed to be directly linked to the expression of the inhibitory IFN-␥-receptor ␤-chain and to the presence of accessory cells. 50 -53 In addition to IL-12, IL-7 was shown to act synergistically with CD80-mediated costimulation on the proliferation of T lymphocytes. 45, 46 Furthermore, IL-7 was shown to enhance the immunogenicity of murine CD80-transfected tumor cells, even if those tumors failed to elicit a sufficient antitumor response. 44 Possible mechanisms might be the induction of several cytokines (IL-2, IL-4, IL-12, TNF, GM-CSF) augmenting tumor Ag presentation by APCs, and an up-regulation of cytokine receptors on the corresponding T cells. 44 -46 Our results from primary and long-term stimulations of T lymphocytes with CD80-transfected breast and ovarian carcinoma cells support the cooperative effect of IL-7 and CD80 costimulation.
To analyze T-cell effector functions, we established long-term MLTCs by adding IL-12 after T-cell priming with tumor cells alone. In all cases, IL-12 was only able to promote proliferation in cooperation with CD80-mediated costimulation. The observation that the timing of the addition of IL-12 to MLTCs is critical (almost no inhibitory effect was observed if added at day 3 or later or in secondary stimulations) may be explained by the finding that preactivated T cells produced less IFN-␥ when restimulated with CD80-transfected tumor cells and did not respond to exogenous IFN-␥. 47 IL-12 was reported to activate NK activity predominantly and to augment CTL development. 32, 33 Indeed, the NK activity of T cells expanded with CD80 ϩ KS24 cells in the presence of IL-12 was higher during the first four stimulation cycles compared with T lymphocytes stimulated with CD80 ϩ KS24 cells alone. However, at later timepoints, increased cytolysis of parental KS cells by predominantly CD8
ϩ T cells was observed. In contrast, the T-cell lines generated in the presence of IL-7 turned out to consist mainly of CD4 ϩ T cells exhibiting less LA toward the parental tumor lines.
Several clinical studies were initiated to investigate the therapeutic potential of CD80-transfected tumor cell vaccines in combination with different cytokines. To circumvent the requirement for generating individual vaccines for each patient, allogeneic cell lines with shared HLA alleles inducing responses against common tumor Ags are under investigation. These studies are based on the finding that T cells specific for shared tumor Ags can be generated by stimulation with HLAmatched allogeneic tumor cell lines as demonstrated in the case of melanoma. 54, 55 Our results suggest that the coapplication of IL-12 with CD80-transfected tumor cells in a clinical protocol could be harmful and inhibit tumor-specific responses. In this regard, the use of CD86-expressing tumor cell vaccines may have an advantage over CD80-transfected lines. 48 IL-12, when used under appropriate conditions in vitro, can act as a T-cell growth factor. Here, we demonstrated that IL-12 allows the continuous in vitro expansion of T cells to obtain sufficient cell numbers to be used in adoptive transfer during cellular immunotherapy.
